Viking Therapeutics
Viking Therapeutics is a clinical-stage drug developer whose experimental obesity and diabetes injections are meant to mimic GLP-1, a gut hormone that controls appetite, placing it among makers of GLP-1 drugs.
Checked against the company's own business description in its latest annual filing.
Latest disclosed
10-Q filed 2026-07-29 · period ending 2026-06-30
Pieces naming this company
None yet.
No price is shown: the Index is a map of what each company sells and where it sits, not a quote board.